Andrew Loblaw/whiff-of-grape.ca
May 4, 2025, 10:39
Andrew Loblaw: 20 year Data Propensity-based analysis of LDR vs HDR boost
Andrew Loblaw, Prostate Cancer researcher at Sunnybrook Health Sciences Centre, shared a post on X:
“Dr Goni Ramirez presents 20y data propensity-based analysis of LDR v HDR boost.
N=546 matched, both CT planned.
LDR = HDR for bDFS, MFS, CSS.
But LDR > HDR for late GU G3+ toxicity (20% at 10y!).
Maybe real-time HDR and IO LDR planning will risk?”
Stay tuned to OncoDaily for continued coverage and updates from ESTRO25.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
May 4, 2025, 13:27
May 4, 2025, 13:12
May 4, 2025, 12:59
May 4, 2025, 12:45